Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), today reported its financial results and business update for the three and nine months ended September 30, 2014.
“With the recent closing of a $200 million private offering, Synergy is now fully funded to successfully drive both plecanatide chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) pivotal phase 3 clinical development programs through to NDA filing,” said Dr. Gary S. Jacob, Chairman and CEO of Synergy Pharmaceuticals Inc.
Help employers find you! Check out all the jobs and post your resume.
